Rocket Pharmaceuticals, Inc. Payments to Acquire Productive Assets
Rocket Pharmaceuticals, Inc. (RCKT) reported Payments to Acquire Productive Assets of $70.00 thousand for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-07.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireProductiveAssets · last filed 2018-03-07
- Rocket Pharmaceuticals, Inc. payments to acquire productive assets for the quarter ending 2017-12-31 was $0.00, a 100.00% decline year-over-year.
- Rocket Pharmaceuticals, Inc. payments to acquire productive assets for the quarter ending 2017-09-30 was $0.00, a 100.00% decline year-over-year.
- Rocket Pharmaceuticals, Inc. payments to acquire productive assets for the quarter ending 2017-06-30 was $17.00K, a 92.31% decline year-over-year.
- Rocket Pharmaceuticals, Inc. payments to acquire productive assets for the quarter ending 2017-03-31 was $53.00K, a 253.33% increase year-over-year.
- Rocket Pharmaceuticals, Inc. payments to acquire productive assets for fiscal 2017 was $70.00K, a 85.63% decline from fiscal 2016.
- Rocket Pharmaceuticals, Inc. payments to acquire productive assets for fiscal 2016 was $487.00K, a 18.20% increase from fiscal 2015.
- Rocket Pharmaceuticals, Inc. payments to acquire productive assets for fiscal 2015 was $412.00K.
| Period end | Payments to Acquire Productive Assets 3 month | Payments to Acquire Productive Assets 6 month | Payments to Acquire Productive Assets 9 month | Payments to Acquire Productive Assets 12 month |
|---|---|---|---|---|
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | $0.00 derived: sum of 2 quarters · filed 2018-03-07 | $17.00K derived: sum of 3 quarters · filed 2018-03-07 | $70.00K 10-K · filed 2018-03-07 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $17.00K derived: sum of 2 quarters · filed 2017-11-08 | $70.00K 10-Q · filed 2017-11-08 | $213.00K derived: sum of 4 quarters · filed 2018-03-07 |
| 2017-06-30 | $17.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $70.00K 10-Q · filed 2017-08-03 | $213.00K derived: sum of 3 quarters · filed 2018-03-07 | $321.00K derived: sum of 4 quarters · filed 2018-03-07 |
| 2017-03-31 | $53.00K 10-Q · filed 2017-05-10 | $196.00K derived: sum of 2 quarters · filed 2018-03-07 | $304.00K derived: sum of 3 quarters · filed 2018-03-07 | $525.00K derived: sum of 4 quarters · filed 2018-03-07 |
| 2016-12-31 | $143.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | $251.00K derived: sum of 2 quarters · filed 2018-03-07 | $472.00K derived: sum of 3 quarters · filed 2018-03-07 | $487.00K 10-K · filed 2018-03-07 |
| 2016-09-30 | $108.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $329.00K derived: sum of 2 quarters · filed 2017-11-08 | $344.00K 10-Q · filed 2017-11-08 | $438.00K derived: sum of 4 quarters · filed 2017-11-08 |
| 2016-06-30 | $221.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $236.00K 10-Q · filed 2017-08-03 | $330.00K derived: sum of 3 quarters · filed 2017-08-03 | $618.00K derived: sum of 4 quarters · filed 2017-08-03 |
| 2016-03-31 | $15.00K 10-Q · filed 2017-05-10 | $109.00K derived: sum of 2 quarters · filed 2017-05-10 | $397.00K derived: sum of 3 quarters · filed 2017-05-10 | |
| 2015-12-31 | $94.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $382.00K derived: sum of 2 quarters · filed 2017-03-16 | $412.00K 10-K · filed 2017-03-16 | |
| 2015-09-30 | $288.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $318.00K 10-Q · filed 2016-11-09 | ||
| 2015-06-30 | $30.00K 10-Q · filed 2016-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |